Danielle Antalffy

what gives you confidence that these are the right prices that you're landing at today to drive that volume increase

how you see, left atrial appendage closure evolving for Abbott Laboratories specifically in in 2026 and beyond

I just have to imagine that, that could actually accelerate Amulet growth

I'm thinking like heart failure, peripheral, and maybe how you're thinking about elevating those growth profiles in 2025

where you see the most exciting opportunities with the current portfolio that might be underappreciated by investors, and b) where you think there is opportunity to ramp up the product portfolio

just curious, Brent, Heather, Joel, if you guys could provide some commentary on how you're thinking about when Baxter or maybe even just broadly the approach to organic versus inorganic investment

any color you can give on sizing these and what we as analysts and investors can look forward to over the next 12 to 24 months?

what's playing out in the real world as far as capacity at the EP lab because a lot of the docs we talk to sound like they have growing waitlist

I'm just curious about how you think about the cadence of growth in that business as we start to get into the launch of some of those new products

at what point do we start to see capacity be an issue? And I guess the -- are you seeing that yet?

what your expectations are, if you can comment on timing for that acquisition?

where you think Boston Scientific Corporation's either underperforming or under-indexed, but see an opportunity

how to think about utilization based on what you know today

it sounds like that is assuming no expanded coverage. I mean how -- what are your latest thoughts on potential for expanded coverage in 2026

Can you talk about what you guys are doing as they start to get close to launching in that patient population and how you're going to protect your competitive moat there

how exposed or unexposed or protected you guys think you are if, in fact, we go into a recession

as more of these non-insulin using type two patients come online, how should we think about that

Do you see that seventy percent moving higher, or do you think that's, like, sort of the aspirational peak

is it fair to think of the med tech business as a closer to high single-digit growth business?

do we or don't we go into a recession? And I'd love some color, if as much as you can provide on how you guys think about your business

I'm just curious what goes into actually developing this market, building out -- helping centers build out referral networks, et cetera. And if you could give any color on actual numbers to date ev...

how to think about the ramp from just over $1 billion to $2 billion in that CAS business. I mean, is that something that based on your commentary

I'd just love to get a state of the nation on the TAVR market. And where do you see that going from here, especially with a recent asymptomatic data that we saw

I specifically wanted to see if you could talk a little bit about the sampling at the physician's office

I was just curious if maybe you could talk a little bit about the difference in the go-to-market strategy, number one, between the two

sort of how the go-to-market strategy with primary care differs from endocrinologists

I'm just curious about how you're seeing potentially your hospital customers, ASP customers are they changing the way they're contracting at or on price

specifically in Ortho, do you think it's more like flat going forward from here? Or do you still have pricing power there, too

Is there anything structural about the international market that would make the ramp look different for Mako than it did in the U.S.?

there's been a lot of been very -- evolving very quickly with tariffs, but also the broader health care market in China

I'm just curious if you guys could talk about how recession-proof or not or where you see the most exposure to your businesses?

how do we think about R&D spend going forward? I appreciate you guys for 2025 has given some goalpost there. But just at a high level

what gives you the confidence. Appreciate a third has been done so far

how far into that you are and sort of how we should think about that potentially impacting the next few quarters

how you think of Monogram and ROSA coexisting, what you think it brings to the robotics market overall in addition to what you have with ROSA

I wanted to dive a little bit more into the ASC opportunity because I think that's a potentially meaningful growth driver